NAGLU Protein (Alpha-N-Acetylglucosaminidase)

NAGLU Protein — Alpha-N-Acetylglucosaminidase

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">NAGLU Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Alpha-N-Acetylglucosaminidase</td></tr>
<tr><td><strong>Gene</strong></td><td>[NAGLU](/genes/naglu)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P54802" target="_blank">P54802</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>4MKV, 4O3G, 5V6W</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>73.9 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Lysosome</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Glycosyl hydrolase family 89</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

NAGLU Protein — Alpha-N-Acetylglucosaminidase

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">NAGLU Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Alpha-N-Acetylglucosaminidase</td></tr>
<tr><td><strong>Gene</strong></td><td>[NAGLU](/genes/naglu)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P54802" target="_blank">P54802</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>4MKV, 4O3G, 5V6W</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>73.9 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Lysosome</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Glycosyl hydrolase family 89</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

NAGLU (Alpha-N-Acetylglucosaminidase) is a lysosomal enzyme that plays a critical role in the degradation of glycosaminoglycans (GAGs), specifically heparan sulfate. This enzyme is essential for normal lysosomal function and cellular homeostasis. The NAGLU gene encodes a 739-amino acid protein with a molecular weight of approximately 73.9 kDa, which is targeted to the lysosome via mannose-6-phosphate receptor-mediated trafficking. The enzyme catalyzes the hydrolysis of terminal N-acetylglucosamine residues from the non-reducing end of heparan sulfate chains during the sequential degradation of these complex polysaccharides. This process occurs within the lysosome, where a series of enzymes work in concert to break down heparan sulfate into its component monosaccharides for recycling and reuse by the cell.

Mutations in the NAGLU gene cause Sanfilippo syndrome type B (MPS IIIB), a severe lysosomal storage disorder characterized by accumulation of heparan sulfate in cells throughout the body, particularly in the brain. This accumulation leads to progressive neurodevelopmental regression, including severe intellectual disability, behavioral problems, and early death. Beyond its role in inherited metabolic disease, NAGLU dysfunction has been implicated in more common neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). Lysosomal dysfunction is a hallmark of these age-related disorders, and alterations in NAGLU expression or activity may contribute to disease progression through effects on protein degradation, autophagy, and cellular homeostasis[@fernandes2019][@wang2020].

Structure

Primary Structure

The human NAGLU protein consists of 739 amino acids with the following domain organization:

Signal Peptide (residues 1-22): N-terminal signal sequence for targeting to the endoplasmic reticulum, cleaved during processing to produce the mature enzyme.

Catalytic Domain (residues 100-600): Contains the active site with catalytic residues, belongs to the glycosyl hydrolase family 89, characterized by a TIM-barrel fold.

C-terminal Region (residues 600-739): Contains additional structural elements involved in enzyme stability and lysosomal targeting.

Post-Translational Modifications

• N-linked glycosylation: Multiple sites for N-glycosylation in the N-terminal region
• Phosphorylation: Serine and threonine phosphorylation sites
• Proteolytic processing: Cleavage to produce mature enzyme form

Normal Function

Lysosomal Degradation of Heparan Sulfate

The primary function of NAGLU is the stepwise degradation of heparan sulfate within lysosomes. Heparan sulfate is a complex glycosaminoglycan composed of repeating disaccharide units (glucuronic acid/N-acetylglucosamine) that are sulfated at various positions. The degradation pathway involves multiple enzymes:

This sequential degradation produces monosaccharides that are exported from the lysosome and recycled for new glycan synthesis or energy metabolism.

Tissue Distribution

NAGLU is expressed in most tissues, with highest levels in brain (particularly in neurons and glia), liver (major site of glycosaminoglycan metabolism), kidney, and fibroblasts.

Role in Neurodegeneration

Sanfilippo Syndrome Type B

Mutations in the NAGLU gene cause mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)[@hamilton2017], an autosomal recessive lysosomal storage disorder:

Genetics: Autosomal recessive inheritance, prevalence of 1 in 70,000 to 1 in 200,000 births, over 200 pathogenic variants identified, and correlation between residual enzyme activity and disease severity.

Pathophysiology: Heparan sulfate accumulation in lysosomes causes cellular dysfunction through disruption of normal cellular processes, neuroinflammation with microglial activation and inflammatory responses, and progressive neuronal loss leading to neurodegeneration.

Clinical Features: Normal development in first years of life followed by progressive loss of intellectual function after age 2-6, behavioral problems including hyperactivity, aggression, and sleep disturbances, physical symptoms such as coarse facial features, hearing loss, and joint stiffness, neurological decline with seizures and motor dysfunction, and premature death.

Alzheimer's Disease

NAGLU has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease)[@fernandes2019] through lysosomal dysfunction, which is an early event in AD pathogenesis with impaired degradation and reduced ability to clear protein aggregates. Glycosaminoglycan alterations show heparan sulfate accumulation similar to Sanfilippo syndrome, with heparan sulfate binding to amyloid-beta and influencing tau aggregation.

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), NAGLU contributes to lysosomal dysfunction affecting alpha-synuclein clearance. The autophagy-lysosome pathway defects impair clearance, leading to accumulation of pathological α-synuclein. Microglial activation and chronic neuroinflammation also result from lysosomal dysfunction in glia[@khan2018].

Therapeutic Approaches

Enzyme Replacement Therapy

Enzyme replacement therapy (ERT) has been developed for Sanfilippo B[@biggar2006] using recombinant NAGLU administered intravenously, though with limited CNS penetration. Some benefit for peripheral symptoms has been observed.

Gene Therapy

Gene therapy approaches aim to provide functional NAGLU[@wagner2016] through viral vectors (AAV-mediated gene delivery), CNS targeting via direct brain delivery or peripheral with cross-correction, and ongoing clinical trials.

Small Molecule Approaches

Substrate reduction therapy uses gene expression inhibitors to reduce heparan sulfate production, lessening the metabolic burden. Pharmacological chaperones help mutant enzymes achieve proper conformation and increase residual function.

Key Publications

Cross-References

• [NAGLU Gene](/genes/naglu)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Sanfilippo Syndrome](/diseases/sanfilippo-syndrome)
• [Glycosaminoglycan Metabolism](/mechanisms/glycosaminoglycan-metabolism)
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Autophagy](/mechanisms/autophagy)
• [Neuroinflammation](/mechanisms/neuroinflammation)

External Links

• [UniProt: NAGLU](https://www.uniprot.org/uniprot/P54802)
• [PDB: NAGLU](https://www.rcsb.org/structure/4MKV)
• [NCBI Gene: NAGLU](https://www.ncbi.nlm.nih.gov/gene/4665)

References